REGNRegeneron PharmaceuticalsRunning, no new patients
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 2/3
- Patients
- 160 (final count)
- Started
- Aug 8, 2023
- Main results expected
- Jan 16, 2030
- Fully finished
- Dec 23, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective response rate (ORR) as assessed by blinded independent review committee (BICR) using RECIST 1.1
Measured over: Up to 136 Weeks
Overall Survival (OS)
Measured over: Up to 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05800015 · record last updated 2026-07-15 · checked 2026-11-09 15:47 UTC